Nxera Pharma Co (TSE:4565) Short-Term Debt: 円6,575 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4565 Nxera Pharma Co Ltd TSE:4565
74 GF Score
Price 円1,087.00
GF Value 円831.24
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Nxera Pharma Co Short-Term Debt?

Nxera Pharma Co TSE:4565 +8.48% 74 Short-Term Debt is 円6,575 Mil as of Jun. 2026. GuruFocus rates TSE:4565 with a GF Score™ of 74/100 and a GF Value™ of 円831.24 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Nxera Pharma Co's Short-Term Debt for the quarter that ended in Jun. 2026 was 円6,575 Mil.

Nxera Pharma Co's quarterly Short-Term Debt stayed the same from Dec. 2025 (円5,798 Mil) to Mar. 2026 (円5,798 Mil) but then increased from Mar. 2026 (円5,798 Mil) to Jun. 2026 (円6,575 Mil).

Nxera Pharma Co's annual Short-Term Debt declined from Dec. 2023 (円5,941 Mil) to Dec. 2024 (円5,798 Mil) but then stayed the same from Dec. 2024 (円5,798 Mil) to Dec. 2025 (円5,798 Mil).

Nxera Pharma Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Nxera Pharma Co Short-Term Debt Related Terms

Nxera Pharma Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Nxera Pharma Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nxera Pharma Co Short-Term Debt Chart

Nxera Pharma Co Annual Data
Trend Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 5,941.00 5,798.00 5,798.00

Nxera Pharma Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,798.00 5,798.00 5,798.00 5,798.00 6,575.00
TSE:4565
74GF Score
Nxera Pharma Co Ltd TSE:4565
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of 円6,575 Mil mean?
Nxera Pharma Co (TSE:4565) has a Short-Term Debt of 円6,575 Mil as of Jun. 2026.
Is Nxera Pharma Co's Short-Term Debt too high?
Nxera Pharma Co's current Short-Term Debt is 円6,575 Mil. Overall, Nxera Pharma Co has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nxera Pharma Co's Short-Term Debt compare to VRTX and REGN?
Nxera Pharma Co's Short-Term Debt of 円6,575 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Nxera Pharma Co's current Short-Term Debt is 円6,575 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nxera Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Nxera Pharma Co (TSE:4565) is currently considered Significantly Overvalued. The stock's GF Value™ is 円831.24, compared to a current price of 円1,087.00 — trading 30.8% above its estimated fair value. The current Short-Term Debt is 円6,575 Mil. Nxera Pharma Co's overall GF Score™ is 74/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Nxera Pharma Co (TSE:4565), the current Short-Term Debt is 円6,575 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nxera Pharma Co (TSE:4565) Overvalued in 2026?

Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be overvalued. The current stock price of 円1,087.00 is trading 30.8% above its estimated GF Value™ of 円831.24. GuruFocus considers Nxera Pharma Co to be Significantly Overvalued.

Key valuation signals for TSE:4565:

  • Short-Term Debt: 円6,575 Mil
  • GF Value™: 円831.24 vs. price of 円1,087.00 (30.8% above fair value)
  • GF Score™: 74/100 with 9 warning signs

No single metric tells the full story. See the TSE:4565 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nxera Pharma Co Business Description

Other Exchanges SOLTF:USA
Address Midtown East, 9-7-2 Akasaka Minato-ku, Tokyo, JPN, 107-0052
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
74GF Score

Get the complete analysis for TSE:4565

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,087.00
Price
円831.24
GF Value